ADIPOQ and obesity disorder: Adiponectin levels decrease up to 20–40% during MASLD [81], and low adiponectin levels significantly elevate the risk of adverse cardiovascular events through mechanisms like insulin insensitivity, inflammation, atherosclerosis, enhancement of monocyte adhesion to endothelial cells, and obesity [78,81].